HER2-POSITIVE BREAST-CANCERRECEPTOR STATUSCHEMOTHERAPYTRASTUZUMABNeoadjuvant chemotherapy (NAC) with Anti-Human Epidermal Growth Factor Receptor 2 (Anti-HER2) agents increase rates of pathologic complete response (pCR) in stage II-III, HER2+ breast cancer (BC). Several retrospective studies show HER2 ...
[7]Shen GS,Zhao JD,Zhao JH,et al.Association of HER2 status with prognosis in gastric cancer patients undergoing R0 resection:A large-scale multicenter study in China.World J Gastroenterol 2016;22(23):5406-5414 [8]Liang JW,Zhang JJ,Zhang T,et al.Clinicopathological and prognostic significance...
Women diagnosed with breast cancer face many emotional and psychological challenges, which are often related to how they perceive their chances of survival. A number of factors are known to be indicators of breast cancer prognosis, including tumour type, size and grade, and lymph node status. The...
Towards personalized treatment for early stage HER2-positive breast cancer Article 13 December 2019 Main The discovery of the human epidermal growth factor receptor 2 (HER2) (King et al, 1985; Schechter et al, 1985), its association with poor prognosis in breast cancer (Slamon et al, 1987...
[11]Kurozumi S, Padilla M, Kurosumi M, et al. HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients. Breast Cancer Res Treat. 2016;158(1):99-111. ...
1. Furrer. In: Lemamy, editor. Cancer Prognosis. 2018. 2. Meric-Bernstam. Clin Cancer Res. 2019;25:2033. 3. Yan. Cancer Metastasis Rev. 2015;34:157. 4. Stenehjem. Breast Cancer(Dove Med Press). 2014;6:169. 5. Varga. BMC Cancer. 2013;13:615. ...
V Macrinici,E Romond - 《Clinical Breast Cancer》 被引量: 84发表: 2010年 HER2-positive metastatic breast cancer: A changing scenario Adjuvant trastuzumab (AT) dramatically improved HER2-positive breast cancer prognosis. Relapsed disease after AT has different patterns and information is ... G.,Mu...
Human epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, ner
[8] Horisawa N, Adachi Y, Takatsuka D, et al. The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status. Bre...
1.Tandon A, et al. HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Oncol. 1989;7(8):1120-8. 2.Mitri Z, et al. The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Ad...